Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
ASSOCIATION BETWEEN BASELINE DISEASE CHARACTERISTICS AND RELAPSE-FREE SURVIVAL (RFS) IN PATIENTS (PTS) WITH BRAF V600-MUTANT RESECTED STAGE III MELANOMA TREATED WITH ADJUVANT DABRAFENIB (D) + TRAMETINIB (T) OR PLACEBO (PBO)
19 srpna, 2020 12:55 pmMeeting 2019 ASCO® Annual Meeting Category Melanoma/Skin Cancers Type Poster Session Abstract No 9582 Poster Board...
FIVE-YEAR ANALYSIS ON THE LONG-TERM EFFECTS OF DABRAFENIB PLUS TRAMETINIB (D + T) IN PATIENTS WITH BRAF V600–MUTANT UNRESECTABLE OR METASTATIC MELANOMA
19 srpna, 2020 12:55 pmMeeting 2019 ASCO® Annual Meeting Category Melanoma/Skin Cancers Type Oral Abstract Session Abstract No 9507 Citation...
RETROSPECTIVE ANALYSIS OF PATIENTS WITH SENTINEL LYMPH NODE (SLN) POSITIVE MELANOMA (MEL) WHO RECEIVED ADJUVANT NIVOLUMAB (NIVO) WITHOUT COMPLETION LYMPH NODE DISSECTION (CLND)
19 srpna, 2020 12:55 pmMeeting 2019 ASCO® Annual Meeting Category Melanoma/Skin Cancers Type Poster Session (Monday, June 3, 2019) Abstract No...
UNITED STATES INTERGROUP E1609: A PHASE III RANDOMIZED STUDY OF ADJUVANT IPILIMUMAB (3 OR 10 MG/KG) VERSUS HIGH–DOSE INTERFERON-α2B FOR RESECTED HIGH-RISK MELANOMA
19 srpna, 2020 12:55 pmMeeting 2019 ASCO® Annual Meeting Category Melanoma/Skin Cancers Type Oral Abstract Session (Tuesday, June 4, 2019) Abstract...
Zpráva z ASCO® 2019 – melanom
19 srpna, 2020 12:55 pmNa letošním ASCO® bylo prezentováno celkem 606 sdělení, která se zabývala problematikou melanomu. Od roku 2011, kdy jich bylo pouze 249, se...
CLINICAL AND GENOMIC RISK TO GUIDE THE USE OF ADJUVANT THERAPY FOR BREAST CANCER
19 srpna, 2020 12:54 pmBackground The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score...
PHASE III MONALEESA-7 TRIAL OF PREMENOPAUSAL PATIENTS WITH HR+/HER2− ADVANCED BREAST CANCER TREATED WITH ENDOCRINE THERAPY ± RIBOCICLIB: OVERALL SURVIVAL RESULTS
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Breast Cancer – Metastatic / Hormone Receptor-Positive Type Oral Abstract Session (Tuesday,...
CAPIVASERTIB (AZD5363) PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT AFTER RELAPSE OR PROGRESSION ON AN AROMATASE INHIBITOR IN METASTATIC ER-POSITIVE BREAST CANCER (FAKTION): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Breast Cancer – Metastatic Type Oral Abstract Session (Tuesday, June 4, 2019)...
IMPASSION130: UPDATED OVERALL SURVIVAL (OS) FROM A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) + NAB-PACLITAXEL (NP) IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Breast Cancer – Metastatic Type Oral Abstract Session (Tuesday, June 4, 2019)...
SOPHIA PRIMARY ANALYSIS: A PHASE 3 (P3) STUDY OF MARGETUXIMAB (M) + CHEMOTHERAPY (C) VERSUS TRASTUZUMAB (T) + C IN PATIENTS (PTS) WITH HER2+ METASTATIC (MET) BREAST CANCER (MBC) AFTER PRIOR ANTI-HER2 THERAPIES (TX)
19 srpna, 2020 12:54 pmMeeting 2019 ASCO® Annual Meeting Category Breast Cancer – Metastatic Type Oral Abstract Session (Tuesday, June 4, 2019)...